Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In
Skip Navigation LinksCVMBS Home > Veterinary Teaching Hospital > For Veterinarians > Clinical Trials > Efficacy of Immunotherapy for the Treatment of Ocular Squamous Cell Carcinoma in the Horse
Efficacy of Immunotherapy for the Treatment of Ocular Squamous Cell Carcinoma in the Horse
Who qualifies?

Horses with suspected eyelid or limbal (cornea and conjunctiva) squamous cell carcinoma (SCC). Horse will undergo a full ophthalmic and physical exam at their initial visit as well as a biopsy of the suspected tumor. Horses with confirmed eyelid or limbal SCC can be enrolled in studies evaluating immunotherapy as a new type of treatment modality.

Purpose of the study

The aim of these studies are to assess the safety and efficacy of immunotherapy for treatment of ocular SCC in the horse. Horses may qualify for a different type of immunotherapy depending on the location of their tumor. Horses with eyelid SCC can be enrolled into a clinical trial using a series of perilesional injections of Interferon alpha-2b at two week intervals.

Horses with SCC on the eye itself (limbal) may be treated with a topical and/or perilesional immunotherapy depending on the size and location of the tumor.

What is required?

  • Initial ophthalmic and physical exams as well as biopsy of the tumor to confirm SCC diagnosis
  • Bloodwork and reassessment every 2 weeks
  • Injections around the tumor site every 2 weeks (total of 4) depending on tumor type and location

Benefits

All costs related to the study will be covered including the examinations and study drugs

To enroll

Interested participants can learn more by contacting the Primary Investigator on the studies, Dr. Kathryn Wotman, via email at Kathryn.Wotman@colostate.edu​.

​​​